AVBP · ArriVent BioPharma, Inc. · Executive Compensation
$18.85
+0.91 (+5.07%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$921.31M
Shares
49.31M
Volume · Oct 20
817.87K
Avg daily vol (3M)
1M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Stuart Lutzker | M.D., Ph.D President, Research and Development | $3,431,717 |
| Winston Kung | Chief Financial Officer and Treasurer | $3,407,068 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Winston Kung | MBA .................... Chief Financial Officer and Treasurer | $1,832,573 |
| Stuart Lutzker | M.D., Ph.D.............. President, Research and Development | $985,967 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stuart Lutzker | M.D., Ph.D.............. President, Research and Development | $828,752 |
| Winston Kung | MBA .................... Chief Financial Officer and Treasurer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Merdad Parsey | member of the Compensation Committee of the Board | Appointed | 2025-04-28 |
| Merdad Parsey | director | Appointed | 2025-04-28 |
| John Hohneker, M.D. | Class II Director | Appointed | 2024-05-16 |
| Kristine Peterson | Class III Director | Appointed | 2024-04-22 |
Leadership
- Winston Kung CFO
- Robin LaChapelle COO
- James Kastenmayer General Counsel
- Chris W. Nolet Board Member
- James Healy Board Member
- John Hohneker Board Member
- John Hohneker, M.D. Board Member
- Kristine Peterson Board Member
- Merdad Parsey Board Member
- Merdad Parsey, M.D., Ph.D. Board Member
- Stuart Lutzker Board Member
Key facts
CIK
1868279
CUSIP
04272N102
13F (30d)
10 filings
10 filers
Visit website
Investor relations